Radio and PodcastLive Radio & PodcastsOpening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsFetching podcast shows and categories...
Radio and PodcastLive Radio & PodcastsFetching podcast episodes...
A trusted and essential partner to the biopharmaceutical industry, providing 27 years of in-depth research, analysis and data on innovation and excellence —from biology to the patient.
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the fo...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Researc...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDA...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar polici...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed t...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podc...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCe...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to...
Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese...
The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a succe...
Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change ac...
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for mul...
As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving...
2025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 bi...
RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, mo...
New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted a...
The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode...
Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This...
The J.P. Morgan Healthcare Conference kicked off this week with sunny skies over San Francisco and more financial momentum than the biotech...
Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital...
The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun...
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key tre...
Obesity readouts continue to be hot for biotech with new top-line data from both injectable and oral therapies pushing the boundaries on eff...
Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three we...
Novo Nordisk’s highly anticipated data for semaglutide in Alzheimer’s dashed hopes that the GLP-1 therapy could become a game changer in the...
A baffling decision by FDA to issue a complete response letter for a pediatric medicine the medical community stood behind is just the lates...
There is cautious optimism around continued M&A momentum and the public equities markets as biotech heads into the New Year. On a special ed...
Voyager CEO and former head of R&D at Biogen Al Sandrock is more optimistic than ever about the prospect of bringing clinically meaningful s...
Richard Pazdur took the top job at FDA’s Center for Drug Evaluation and Research after receiving vows that he would be leading CDER free fro...
Today’s South Korean biotechs have a risk-on mentality, a willingness to partner, and strategies focused on globalization. On a special edit...
With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center...
Novo Nordisk’s unsolicited $8.5 billion bid for Metsera has thrown a wrench into Pfizer’s plans to return to the obesity race via its acquis...
China is setting a new bar for the speed of clinical development and redefining the time it takes an asset to get to the clinic. On a specia...
Novartis’ biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish lin...
Next-generation platforms and technologies are getting closer to cracking one of biopharma’s biggest problems: delivering medicines, and mAb...
It’s been a tough year for cell and gene therapy — patient deaths, high-profile companies pulling out of the space, and sour investment sent...
Biotech’s fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and reg...
The short-term consequences for Pfizer from its “most favored nation” drug pricing deal with the White House are negligible, but the long-te...
Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech’s largest step toward marketing its own pipeline....
AI is bringing sweeping changes to drug development, from how targets are discovered to optimizing clinical trials to maximize an asset’s ch...
Is this the U.K.’s moment to capitalize on its biotech ecosystem? That was one of the primary themes discussed at the debut Grand Rounds — E...
A takeout that could be worth as much as $7.3 billion has Pfizer back in the obesity drug development race. On the latest BioCentury This We...
Merck's announcement that it is moving its R&D out of the U.K. highlights concerns about the country’s life sciences policies. On the l...
Molecular biologist and Nobel Prize winner David Baltimore made foundational contributions to the biopharma industry and was the essential f...
Two veteran biotech leaders are launching a new company with ambitions in the cardiovascular disease space. On the latest BioCentury This We...
There’s been a rare IPO filing on NASDAQ as LB Pharma looks to test the market during a year that has seen little activity among U.S. biotec...
BioCentury’s third annual analysis of pharma company deals finds that bispecifics and degraders are in, cell and gene therapies are out, and...
Dealmaking between Western and Chinese biopharmas has been one of the year’s bright spots, as a maturing biotech landscape in China converge...
Phase III data from Lilly’s orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and...